Clinical Trial Update: Pulmonary Artery Pressure Reduction With ENTresto (Sacubitril/Valsartan) [Phase 4]

View source ↗

Summary

A Phase 4 trial update on reducing pulmonary artery pressure with sacubitril/valsartan (ENTresto) in congestive heart failure was terminated with results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure

Drugs mentioned

• Entresto (sacubitril/valsartan)

Snippet

Sponsor: Brigham and Women's Hospital | Conditions: Congestive Heart Failure | Phase 4 | Status: TERMINATED | Results posted: 2020-02-17